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 Introduction 
 Corticosteroids have been used since the 1950s in in-
flammatory bowel disease (IBD) and they remain one of 
the most effective treatments in a disease flare  [1] . These 
drugs represent effective anti-inflammatory agents for in-
ducing response and remission in IBD patients with mod-
erate to severe disease activity. They act via inhibition of 
several inflammatory pathways such as the suppression of 
interleukin transcription, the induction of I  B that stabi-
lizes the NF-  B complex, the suppression of arachidonic 
acid metabolism and the stimulation of lymphocyte apop-
tosis within the lamina propria of the gut  [2] .
 Precise evidence on the most effective dose and dura-
tion of therapy is lacking. Sixty milligrams (mg) of pred-
nisolone seems to not be more effective than 40 mg, but 
it is associated with a higher frequency of adverse events 
 [3] . Guidelines suggest starting with an initial oral dose 
of 40–60 mg (0.75–1 mg/kg) prednisolone daily followed 
by a tapering  [4, 5] . A commonly used regimen for steroid 
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 Background and Aims: Although systemic corticosteroids 
are successfully administered for the induction of clinical re-
sponse and remission in the majority of patients with inflam-
matory bowel disease (IBD) presenting with a flare, a propor-
tion of these patients demonstrate a primary nonresponse 
to steroids or in the case of an initial response, they develop 
a resistance or a steroid dependence. Long-term therapy 
with corticosteroids for treatment of IBD should be avoided, 
given the high frequency of adverse treatment effects. 
Knowledge about treatment strategies in case of steroid 
nonresponse is therefore highly relevant.  Methods: A sys-
tematic literature research was performed using Medline 
and Embase to summarize the currently recommended 
treatment strategies for steroid-resistant IBD.  Results: Treat-
ment of steroid-resistant Crohn’s disease is based on the in-
troduction of immunomodulators such as azathioprine, 
6-mercaptopurine or methotrexate, the anti-TNF drugs inf-
liximab, adalimumab and certolizumab pegol. In the case of 
steroid resistance in ulcerative colitis, aminosalicylates, the 
above-mentioned immunomodulators, infliximab, adalimu-
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tapering consists of reducing dosages above 30 mg daily 
in 10-mg steps per week and reducing dosages of 30 mg 
daily and below in 5-mg steps per week. Neither the long-
term remission rates nor the duration of remission is in-
fluenced by the initial dose or the rate of steroid tapering 
 [5, 6] . The goal of every IBD therapy is the achievement 
of a steroid-free remission. Steroids have no role as main-
tenance therapy in either Crohn’s disease (CD) or ulcer-
ative colitis (UC)  [7] .
 About half the patients treated with steroids will suffer 
from side effects. Following the administration of supra-
physiological doses of steroids, cosmetic problems (e.g. 
acne, moon-face and edema), diabetes, dyspepsia or sleep 
and mood disturbances may occur. Furthermore, pa-
tients on steroids are confronted with an increased risk 
for infections. Prolonged use of steroids has been associ-
ated with osteoporosis, osteonecrosis, myopathy and cat-
aracts. In addition, children and adolescents may suffer 
from growth retardation. Typical steroid-withdrawal ef-
fects include adrenal insufficiency, the corticoid-with-
drawal syndrome and raised intracranial pressure  [2] .
 The natural history of first exposure to corticosteroids 
shows a 30-day outcome of complete remission in 48–
58% of CD patients, a partial remission in 26–32% and no 
response in 16–20%  [6, 8] . In UC, immediate outcomes 
were complete remission in 54%, partial remission in 30% 
and no response in 16% of the patients  [8] .
 The phenomenon of steroid resistance is not confined 
to IBD, suggesting that it may be an inherent property of 
an individual which becomes important in the presence 
of inflammatory disease  [1] . Several molecular mecha-
nisms of glucocorticoid resistance have now been identi-
fied, including the activation of mitogen-activated pro-
tein kinase pathways by certain cytokines, the excessive 
activation of the transcription factor activator protein 1, 
reduced histone deacetylase-2 expression, raised macro-
phage migration inhibitory factor and increased P-glyco-
protein-mediated drug efflux  [9] .
 Definition of Steroid-Resistant and
Steroid-Dependent Disease 
 IBD patients who have still active disease, despite 
prednisolone or an equivalent of up to 0.75 mg/kg/day 
over a period of 4 weeks, are defined as having steroid-
resistant or steroid-refractory disease. Patients who are 
either unable to reduce steroids below the equivalent of 
prednisolone 10 mg/day within 3 months of starting 
without recurrent active disease, or who have a relapse 
within 3 months of stopping steroids are considered as 
having steroid-dependent disease  [10–13] .
 Steroid resistance, dependence or a primary nonre-
sponse should prompt an escalation of medical treat-
ment, alternatively, surgery should be considered.
 Steroid Resistance in Crohn’s Disease 
 Before increasing or changing therapy in steroid-resis-
tant CD, complications such as an abscess or infection 
must be ruled out by appropriate imaging techniques or 
stool analyses. Furthermore, surgery should also be con-
sidered as an option, especially in CD patients with severe 
ileocecal involvement. Different treatment strategies 
have been shown to be effective for steroid resistance; 
these will now be further discussed below. 
 Purine Analogs 
 Thiopurine drugs, represented by mercaptopurine (6-
MP) and its prodrug azathioprine (AZA) have cytotoxic 
and immunosuppressive properties. The appropriate 
maintenance dose is 2–2.5 mg/kg/day of AZA and 1–1.5 
mg/kg/day of 6-MP, respectively. They are widely used in 
steroid-refractory or steroid-dependent IBD patients. 
They have proven efficacy for the induction of remission 
in active CD and for maintaining remission and having 
steroid-sparing properties in quiescent steroid-depen-
dent CD  [14–17] . In the recent SONIC study, 30% of the 
170 patients receiving AZA alone had a corticosteroid-
free clinical remission after 6 months  [18] . About 9% of 
IBD patients are resistant to thiopurines and between 15 
and 28% experience adverse reactions  [19] .
 Methotrexate 
 Methotrexate (MTX) 25 mg/week (oral, subcutaneous 
or intramuscular) may be used as an alternative to thio-
purines. This is an established therapy for the induction 
and maintenance of remission in CD  [20, 21] . Injections 
might be preferred due to unpredictable intestinal ab-
sorption via the oral route  [22] .
 Anti-TNF Therapies 
 There are currently three biologic agents licenced for 
the treatment of CD in Switzerland: infliximab (Remica-
de  ) and adalimumab (Humira  ) are monoclonal IgG1 
anti-TNF antibodies and certolizumab pegol (Cimzia  ) 
is a pegylated anti-TNF Fab-antibody fragment. These 
three anti-TNF agents have proven efficacy in CD in var-
ious controlled trials. Most of these trials did not explic-
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itly address steroid resistance but were used in patients 
with moderate to severe disease.
 The European Crohn’s and Colitis Organisation states 
in their consensus statement from 2010 that patients with 
evidence of active disease refractory to steroids should be 
treated with anti-TNF therapy, with or without thiopu-
rines or MTX (EL1a, RG B for infliximab)  [4] . They also 
state that all currently available anti-TNF therapies appear 
to have similar efficacy and adverse-event profiles, so the 
choice depends on availability, route of delivery, patient 
preference, cost and national guidelines  [4] .
 Infliximab 
 The randomized, double-blind S ONIC study assessed 
the efficacy of infliximab with or without AZA in 508 
adult patients with moderate to severe CD naïve to biolog-
ics and immunosuppressants. Remarkably, at baseline, 
only 27.4% of patients were on systemic corticosteroids. 
Patients were randomized to receive AZA monotherapy, 
infliximab monotherapy or infliximab plus AZA combi-
nation therapy. Infliximab was administered at a dose of 
5 mg/kg at weeks 0, 2, 6 and then every 8 weeks. AZA was 
given at a dose of 2.5 mg/kg daily. The primary end point 
of the study was corticosteroid-free clinical remission at 
week 26. Of the patients receiving combination therapy,
at week 26, 56.8% were in corticosteroid-free clinical re-
mission compared to 44.4% receiving infliximab only
(p = 0.02) and 30.0% receiving azathioprine only (p  ! 
0.001 for the comparison with combination therapy and 
p = 0.006 for the comparison with infliximab). Similar 
numerical trends were found at week 50  [18] .
 The GETAID (Groupe d’Etude Thérapeutique des 
Affections Inflammatoires  Digestives) trial evaluated 
the usefulness of short-term infliximab combined with 
thiopurines in steroid-dependent CD patients. One hun-
dred and thirteen steroid-dependent patients with active 
CD were stratified into 2 groups: AZA/6-MP failures 
and AZA/6-MP-naïve patients. Patients were random-
ized to infliximab 5 mg/kg or placebo at weeks 0, 2 and 
6. All patients were treated with stable doses of AZA/6-
MP throughout the 52-week trial. Their primary end 
point was clinical remission [Crohn’s Disease Activity 
Index (CDAI)  ! 150] off steroids at week 24. Significant-
ly more patients receiving infliximab plus AZA/6-MP 
compared with patients receiving AZA/6-MP alone 
were in steroid-free clinical remission at week 12 (75 vs. 
38%; p  ! 0.001) and week 24 (57 vs. 29%; p = 0.003). They 
concluded that infliximab plus AZA/6-MP was more ef-
fective than AZA/6-MP alone in steroid-dependent CD 
patients  [23] .
 Adalimumab 
 In the CLASSIC-I trial, several dosage regimens were 
compared to placebo for the induction of remission in 299 
anti-TNF-naïve patients with moderate to severe CD  [24] . 
Patients were randomized to receive subcutaneous injec-
tions at weeks 0 and 2 with adalimumab 40/20 mg, 80/40 
mg or 160/80 mg or placebo. In the placebo group (n = 74), 
34% (n = 25) were on steroids and 30% on immunomodu-
lators (AZA, 6-MP or MTX) compared to 32% on steroids 
and 29% on immunomodulators in the groups that were 
treated with adalimumab (n = 225). The highest remission 
rate (defined as CDAI  ! 150 points at week 4) was observed 
with 36% (p = 0.001) in the 160/80-mg group compared to 
12% in the placebo group. The percentage of patients off 
steroids at week 4 was not assessed as an end point in this 
study  [24] . In the CHARM trial (Crohn’s trial of the fully 
Human antibody Adalimumab for Remission Mainte-
nance), patients received open-label induction therapy 
with adalimumab 80 mg (week 0) followed by 40 mg (week 
2). At week 4, patients were stratified by response (a drop 
in CDAI of at least 70 points) and randomized to double-
blind treatment with placebo, adalimumab 40 mg every 
other week (e.o.w.) or adalimumab 40 mg weekly up to 
week 56.  [25] End points were the percentage of random-
ized responders achieving clinical remission at weeks 26 
and 56. The percentage of randomized responders in re-
mission was greater in the adalimumab 40-mg-e.o.w. and 
40-mg-weekly groups compared to the placebo group at 
week 26 (40, 47 and 17%, respectively; p  ! 0.001) and week 
56 (36, 41 and 12%, respectively; p  ! 0.001). Forty-four per-
cent of patients were on steroids and 47% on immunomod-
ulators (AZA, 6-MP or MTX). At week 26, out of the ran-
domized responders, 3, 35 and 30% of patients treated with 
placebo, adalimumab 40 mg e.o.w. and adalimumab 40 mg 
weekly, respectively, achieved a corticosteroid-free remis-
sion (p  ! 0.001 for each adalimumab group compared to 
placebo). At week 56, 6, 29 and 23% of patients treated with 
placebo, adalimumab 40 mg e.o.w. and adalimumab 40 mg 
weekly, respectively, achieved corticosteroid-free remis-
sion (p  ! 0.001 for adalimumab 40 mg e.o.w. vs. placebo 
and p = 0.008 for adalimumab 40 mg weekly vs. placebo). 
 Certulizumab Pegol 
 In the PRECISE (Pegylated Antibody Fragment Eval-
uation in Crohn’s Disease Safety and Efficacy) 2 trial, 
patients with moderate to severe CD received induction 
therapy with 400 mg certolizumab pegol s.c. at weeks 0, 
2 and 4  [26] . Patients with a clinical response (CDAI re-
duction of at least 100 points from baseline) at week 6 
were stratified according to their baseline C-reactive 
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protein level and randomly assigned to 400 mg of cer-
tolizumab pegol or placebo every 4 weeks up to week 24 
with a follow-up till week 26. Sixty-four percent of pa-
tients (428 of 668) showed a response at week 6, the re-
sponse was maintained till week 26 in 62 % of patients 
with a baseline CRP of at least 10 mg/l receiving certo-
lizumab pegol compared to 34% in the placebo group
(p  ! 0.001). In the placebo group, 21% (n = 44) of patients 
were on corticosteroids and 25% (n = 52) on immuno-
modulators compared to 22% (n = 47) on steroids and 
27% (n = 59) on immunomodulators in the certolizumab 
group. The percentage of steroid-free patients at week 26 
was not reported in this trial. Neither the response rate 
nor the remission rate differed significantly between the 
2 patient groups i.e. those who were and those who were 
not on concomitant steroids or immunomodulators, or 
both. 
 Steroid Resistance in Ulcerative Colitis 
 Steroid-dependency in UC defines a patient, who fails 
to taper steroid doses below 10 mg within 16 weeks (start-
ing dose 0.75–1 mg/kg oral prednisone-equivalent) or 
who relapses within 12 weeks after the discontinuation of 
steroid treatment. A patient not responding to 0.75–1 mg/
kg of oral prednisone equivalent within 4 weeks is defined 
as having steroid-refractory or steroid-resistant UC  [10, 
27] . This classification is made after the exclusion of infec-
tion by appropriate stool tests and is best reassessed by 
sigmoidoscopy/colonoscopy with biopsies to confirm the 
diagnosis and/or to rule out complications like cytomega-
lovirus colitis or cancer. The universal goal, as in CD, is to 
withdraw steroids completely whenever possible.
 Practical treatment algorithms for moderate to severe 
UC are provided in recent Swiss consensus recommenda-
tions  [28] .
 In steroid-refractory UC in a patient in a clinically sta-
ble condition without the need for rapid induction, thio-
purines (AZA 2–2.5 mg/kg or 6-MP 1–1,5 mg/kg) can be 
administered  [29] . Unlike in CD, the efficacy of thiopu-
rines in UC has been proven for maintenance therapy, but 
only as an alternative treatment  [30] . It may be worth try-
ing to optimize conventional treatment, especially to 
maximise the dose of 5-ASA treatment or to add topical 
5-ASA  [22] .
 If the patient is still clinically stable but not responding 
after 12–24 weeks, biological therapy must be considered.
 The efficacy of infliximab in UC was demonstrated in 
2 large clinical trials. In the ACT-1 and ACT-2 (Active 
Ulcerative Colitis Trials 1 and 2) studies, patients with 
moderate to severely active UC received induction with 
infliximab at weeks 0, 2 and 6, followed by maintenance 
infusions every 8 weeks. Infliximab was superior to pla-
cebo for achieving clinical response, clinical remission, 
mucosal healing and reducing corticosteroid use up to 
weeks 30 (ACT-2) and 54 (ACT-1)  [31] .
 The ACT-1 and ACT-2 extension studies could reveal 
that long-term treatment with infliximab was effective 
and well tolerated for up to 3 additional years  [32] . In a 
retrospective multicenter study primary nonresponse to 
infliximab was noted in 22% of patients  [33] .
 Recently, adalimumab was also shown to be more ef-
fective than placebo in inducing and maintaining clinical 
remission in patients with moderate to severe UC in a 
large trial with 494 patients  [34] . The drug was adminis-
tered subcutaneously: 160 mg at week 0, 80 mg at week 2 
and then 40 mg e.o.w.
 In the severely ill, hospitalized patient with the need 
for rapid induction, steroids are administered intrave-
nously, such as 60 mg of methylprednisolone or 400 mg 
of hydrocortisone daily  [29] . The overall response rate of 
steroids can be expected to be 67%  [35] . A close teamwork 
between the gastroenterologist and the experienced 
colorectal surgeon is mandatory at this stage of the dis-
ease (at the latest), in order not to miss the best timing for 
colectomy.
 In case of resistance to intravenous steroids, especially 
in the AZA-naïve patient, intravenous cyclosporine at a 
dose of 2mg/kg can be started  [28] . If the patient is re-
sponding, AZA is added and oral cyclosporine is contin-
ued for at least 3 months as a bridging therapy  [28] .
 If the severely ill patient had failed prior therapy with 
AZA/6-MP, due to the lack of a good exit strategy, inflixi-
mab at 5mg/kg at weeks 0, 2 6 and then every 8 weeks can 
be started  [28] .
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